NCT06176729View on ClinicalTrials.gov

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

October 24, 2025

Study Completion Date

October 24, 2027

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Polatuzumab Vedotin, Rituximab, Lenalidomide

polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

collaborator

Peking University First Hospital

OTHER

collaborator

Chinese PLA General Hospital

OTHER

lead

Yan Zhang, MD

OTHER